The second week of August introduced collectively vital updates throughout GI oncology, with knowledgeable posts overlaying gastric most cancers, colorectal most cancers, biliary tract most cancers, cholangiocarcinoma, oesophagogastric adenocarcinoma, pancreatic most cancers, hepatopancreatobiliary cancers, and early-onset colorectal most cancers.
This week’s choice consists of updates on multimodal prehabilitation in gastric most cancers surgical procedure, anti-EGFR rechallenge and potential biomarkers in refractory ctDNA RAS/BRAF wild-type metastatic colorectal most cancers, real-world outcomes of cisplatin, gemcitabine, and durvalumab based on TOPAZ-1 eligibility, and mechanisms of acquired resistance to daraxonrasib in RAS-driven cancers.
Different posts spotlight complete genomic profiling in GI cancers, the part 3 FIGHT-302 trial of pemigatinib in FGFR2-rearranged cholangiocarcinoma, upkeep rucaparib after first-line platinum-based chemotherapy in HER2-negative superior oesophagogastric adenocarcinoma, the Lancet Regional Well being – Europe Collection on early-onset colorectal most cancers, precision oncology trial design challenges in uncommon genomic subgroups, and FAPI PET/CT in hepatopancreatobiliary cancers.
Collectively, these posts replicate the continued evolution of GI oncology throughout prehabilitation, biomarker-driven remedy, real-world proof, molecular profiling, focused remedy, resistance biology, imaging, scientific trial design, and multidisciplinary care.
Maria Wobith — Visceral Surgeon at Nationwide College Hospital | Singapore
“I’m very glad to share the primary publication arising from our work throughout the Worldwide Gastric Most cancers Affiliation Prehabilitation Working Group:
‘Unimodal to Multimodal Prehabilitation in Gastric Most cancers Surgical procedure: Systematic Evaluate of Randomised Managed Trials.’
We systematically reviewed the randomized proof for prehabilitation particularly in sufferers present process gastric most cancers surgical procedure.
Throughout 14 RCTs, prehabilitation confirmed an total favorable sign, however not all prehabilitation seems to be equal.
The clearest advantages had been seen with multimodal applications, significantly when delivered over longer intervals and built-in into the oncological therapy pathway.
Quick-term, unimodal dietary interventions confirmed far more combined outcomes.
Multimodal applications confirmed promising results not solely on postoperative morbidity and purposeful capability, but additionally throughout the broader most cancers therapy pathway, together with tolerance and completion of neoadjuvant chemotherapy.
On the similar time, our overview clearly exhibits the place the sector wants to enhance: 14 trials reported 53 completely different outcomes, methodological high quality was variable, heterogeneity stays excessive, and the knowledge of proof stays low.
For me, probably the most vital conclusions is that prehabilitation shouldn’t be thought-about a one-size-fits-all intervention.
We have to higher perceive which sufferers want which intervention, at what depth, and which outcomes matter most and needs to be measured in a standardized strategy.”
Davide Ciardiello — MD, PhD, Medical Oncologist on the Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, European Institute of Oncology, IEO, IRCCS | Italy
“Rechallenge with anti-EGFR brokers is a therapeutic choice for sufferers with refractory ctDNA RAS/BRAF wild-type metastatic colorectal most cancers.
Nonetheless, the seek for potential biomarkers stays an unmet scientific want.
We performed a person affected person knowledge pooled evaluation of the CAVE-GOIM and CAVE-2 GOIM trials, involving sufferers with ctDNA RAS/BRAF/EGFR-ECD wild-type, MSS/pMMR mCRC who underwent rechallenge with cetuximab with or with out avelumab.
To this point, this represents the most important cohort evaluated for this therapeutic technique.
The info verify the exercise of rechallenge with anti-EGFR brokers.
An fascinating discovering is that the exercise of single-agent cetuximab is maintained whatever the clinicopathological elements investigated.
For therapy with cetuximab plus avelumab, the absence of liver metastases was the one variable related to improved PFS and OS within the multivariable evaluation.
These knowledge verify the potential position of liver metastases as a predictive biomarker of response to immunotherapy in MSS/pMMR mCRC.”
Andrea Casadei Gardini — Affiliate Professor at Università Vita-Salute San Raffaele | Italy
“New publication within the Worldwide Journal of Most cancers.
Proud to share our new work: ‘Outcomes of Cisplatin, Gemcitabine, and Durvalumab Based on TOPAZ-1 Research Eligibility: A Massive International Evaluation in a Actual-World Setting.’
One of many main challenges in oncology is knowing how properly outcomes from randomized scientific trials translate to the sufferers we deal with each day.
On this massive worldwide real-world research of 1,358 sufferers with superior biliary tract most cancers handled with first-line cisplatin, gemcitabine, and durvalumab throughout 55 facilities, virtually one-third of sufferers, 32.9%, wouldn’t have fulfilled the TOPAZ-1 eligibility standards.
Importantly, regardless of their much less favorable baseline traits, outcomes within the TOPAZ-1-out inhabitants remained remarkably near these reported within the experimental arm of TOPAZ-1, with a median OS of 12.5 months versus 12.9 months, and with out an evident improve in toxicity.
Amongst trial-ineligible sufferers, energetic an infection, elevated bilirubin, and ECOG PS >1 emerged as the principle elements related to poorer survival, whereas a number of different conventional exclusion standards didn’t seem to considerably compromise outcomes.
These findings present additional proof that the advantage of chemoimmunotherapy could lengthen past the extremely chosen populations enrolled in randomized trials and spotlight the significance of producing high-quality real-world proof to enhance scientific trials.
A really particular thanks to Federica Loprinzi and Margherita Rimini, co-first authors of this work, and to Lorenza Rimassa and Lorenzo Fornaro, with whom I had the pleasure of sharing senior authorship.
And, after all, an enormous thanks to all our co-authors, investigators, and the 55 collaborating facilities worldwide. This research wouldn’t have been attainable with out such a unprecedented worldwide collaboration.”
Wungki Park — Doctor-Scientist; KRAS and DNA Restore; Translational Analysis; Founding father of sPARKlab and GRIT – GI RAS Modern Therapeutics | United States
“The RAS period is coming into its subsequent chapter.
One of the vital thrilling elements of focused remedy is that each scientific success creates a brand new scientific query.
As RAS inhibitors remodel the therapy panorama, understanding why resistance develops turns into the inspiration for designing the following era of therapies.
Congratulations to Ida Aronchik, Sumit Kar, Kevin Lin, Andrew Aguirre, Mallika Singh, and your entire multidisciplinary crew on this excellent Nature Drugs research defining mechanisms of acquired resistance to daraxonrasib and figuring out rational therapeutic methods to beat them.
I additionally extremely suggest the accompanying Information & Views by Paula Lynch, Teresa Macarulla, and Grainne O’Kane.
It gives a chic synthesis of the place the sector stands at present and the place it’s heading subsequent.
From resistance biology to rational mixtures and biomarker-driven precision oncology, that is precisely how the sector advances.
Scientific commentary informs biology, biology informs the following scientific trial, and every iteration brings us nearer to extra sturdy outcomes for sufferers with RAS-driven cancers.”
Learn the complete article
Federico Nichetti — Medical Oncologist at Veneto Institute of Oncology | Italy
“Take a look at our new work out now in JCO Precision Oncology.
This was the primary research I labored on after becoming a member of the GI crew at Istituto Oncologico Veneto IOV – IRCCS in Padova, so it has a particular private which means.
Past the survival profit and inspiring Kaplan-Meier curves, the paper conveys a really pragmatic message: complete genomic profiling in GI cancers comes with many sensible challenges.
Tumor web site, pattern choice, and timing all matter, and may decide whether or not profiling is possible and clinically helpful.”
Davide Melisi — Affiliate Professor of Medical Oncology on the College of Verona | Italy
“Proud to see the outcomes of the part 3 FIGHT-302 trial printed within the present challenge of the Journal of Scientific Oncology.
FIGHT-302 evaluated pemigatinib versus gemcitabine/cisplatin as first-line therapy for sufferers with superior cholangiocarcinoma harboring FGFR2 rearrangements.
This was the most important randomized first-line part 3 trial of a focused remedy on this molecularly chosen inhabitants.
Regardless of the research closing early following a change within the first-line customary of care, the outcomes are compelling:
• Median PFS: 8.3 versus 6.8 months; HR 0.58, 95% CI 0.39–0.87
• ORR: 47% versus 15%
• Median length of response: 14.2 versus 6.3 months
• No new security indicators had been recognized
Past the scientific outcomes, this publication is especially significant to me as a result of Italy was the main nation worldwide in affected person enrollment for FIGHT-302, with Verona because the top-enrolling Italian web site.
That is one thing our whole crew in Verona could be pleased with.
These outcomes add vital proof supporting precision oncology in cholangiocarcinoma and reinforce why complete molecular profiling needs to be an integral a part of the care pathway for sufferers with superior illness.
Most significantly, my honest thanks go to each affected person and household who participated. With out them, none of this is able to have been attainable.”
Erman Akkus — Medical Oncologist and Inner Drugs Doctor at Ankara College | Türkiye
“Upkeep rucaparib after first-line platinum-based chemotherapy in HER2-negative superior oesophagogastric adenocarcinoma: outcomes from the PLATFORM research.”
Alberto Puccini — Medical Oncologist at Humanitas Most cancers Middle | Italy
“I’m extraordinarily grateful for the chance to co-coordinate, along with Chiara Cremolini, this new The Lancet Regional Well being – Europe Collection on early-onset colorectal most cancers.
This mission has introduced collectively dozens of excellent scientists, colleagues, and buddies, all deeply dedicated to understanding and addressing the alarming rise of early-onset colorectal most cancers.
What makes this initiative significantly particular is its actually multidisciplinary perspective, bringing collectively experience from medical oncology, surgical procedure, gastroenterology, genetics, epidemiology, public well being, and lots of different fields.
Most significantly, we had been privileged to have the direct involvement of two distinctive affected person advocates, Laura Daphne Marziali and Yvette Davis, whose views are basic to retaining sufferers’ wants and experiences on the heart of this dialogue.
Over the following few months, the completely different manuscripts of the Collection can be printed, exploring early-onset colorectal most cancers from a number of and complementary views.
An enormous thanks to everybody who has contributed to this bold collaborative effort.
Particular due to Ivana Nedic for the invitation and the collaboration.”
Fen Saj — Analysis Fellow, Medical Oncologist | United States
“Delighted to share our editorial in Nature Opinions Scientific Oncology, coauthored with my mentor Lipika Goyal, on the part 3 FIGHT-302 trial.
This spectacular international effort, led by Tanios Bekaii-Saab and colleagues, examined first-line pemigatinib towards chemotherapy in FGFR2-rearranged cholangiocarcinoma.
The drug improved response charges and PFS, however, like two comparable trials earlier than it, the research closed early as a result of recruitment challenges.
Within the editorial, we talk about a broader problem in precision oncology: standard part 3 designs might not be the best framework for evaluating novel therapies in uncommon cancers with even rarer genomic alterations.
We suggest various methods that would assist bridge this hole.”
Mara Veenstra — MD, PhD Candidate in Radiology and Nuclear Drugs | Netherlands
“I’m very glad to share that our newest research on FAPI PET/CT in hepatopancreatobiliary cancers has now been printed within the European Journal of Nuclear Drugs and Molecular Imaging.
‘Actual-World Proof in a Massive Cohort Evaluating FAPI and FDG PET/CT for Hepatopancreatobiliary Most cancers Analysis.’
That is, to our information, the most important research up to now evaluating the efficiency of FAPI PET/CT throughout HPB malignancies, together with cholangiocarcinoma, gallbladder, pancreatic, periampullary, and hepatocellular carcinoma.
In 176 sufferers who underwent each [¹⁸F]FDG and [⁶⁸Ga]Ga-FAPI-46 PET/CT, we discovered that FAPI PET/CT demonstrated larger sensitivity and diagnostic accuracy than FDG PET/CT, significantly for main tumor and lymph node evaluation.
These findings additional assist the potential position of FAPI PET/CT within the scientific analysis and staging of HPB cancers.
What makes this research particularly significant to me is the worldwide collaboration behind it, bringing collectively colleagues from Erasmus MC in Rotterdam, the Netherlands, and AIG Hospitals in Hyderabad, India.
An enormous thanks to AIG Hospitals for his or her assist, experience, and help all through this mission.
It has been a pleasure working collectively, and we’re already creating new research concepts and dealing towards establishing a long-term collaborative analysis program.”
Discover out 10 Must-Read Posts in GI Oncology from the primary week of August on OncoDaily.
